Senti Biosciences (SNTI) Q4 2025 earnings summary

Executive summary

• Advanced lead program SENTI-202 with positive preliminary Phase 1 data in relapsed/refractory AML, showing encouraging response rates and favorable safety profile.

• Received RMAT designation from FDA for SENTI-202, supporting regulatory momentum.

• Continued progress in pipeline and synthetic biology platform, focusing on Gene Circuit-engineered cell therapies.

• Maintained disciplined capital management to support key milestones.

Financial highlights

• Cash and cash equivalents stood at $16.4 million as of December 31, 2025, down from $48.3 million at year-end 2024.

• Research and development expenses totaled $37.6 million for 2025, up from $34.4 million in 2024.

• General and administrative expenses were $26.2 million for 2025, slightly down from $26.4 million in 2024.

• Net loss for 2025 was $61.4 million, or $2.73 per share, compared to $52.8 million, or $12.03 per share, in 2024.

• Q4 2025 net loss was $14.5 million, or $0.53 per share.

Outlook and guidance

• Focus remains on advancing key programs toward critical development milestones and expanding Gene Circuit platform capabilities.